Arbli Suspension
Product Images NDC 83245-053

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Arbli (NDC 83245-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Scienture Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton Label)

This text seems to be a description of a pharmaceutical product, including details on dosage, storage, and administration instructions. The product is an oral suspension available in different strengths, specified as 10 mg/mL. The text also mentions a recommended dosage and emphasizes the importance of storing and dispensing the product in its original packaging. *

FDA Label Image

Container (Container Label)

This is a description for a medication containing Losartan Potassium in oral suspension form. Each 1 mL of the suspension contains 10 mg of Losartan Potassium. The medication is manufactured by Scienture Inc. and comes in a 165 mL bottle. It should be stored at Controlled Room Temperature and kept out of reach of children. It is important to store and dispense the suspension in its original container.*

FDA Label Image

Figureone (Figure1)

This text provides information on the study timeline related to Atenolol and Losartan in patients with the primary endpoint. It includes the adjusted risk reduction of 13% with a p-value of 0.021. The data is presented over a period of 66 study months.*

FDA Label Image

Figuretwo (Figure2)

FDA Label Image

Figurethree (Figure3)

This text appears to be a comparison or evaluation between two medications, Losartan and Atenolol, in the context of their impact on stroke occurrences, fatal and non-fatal. The text seems to indicate that Losartan is being favored over Atenolol for stroke prevention or treatment based on some data provided.*

FDA Label Image

Figurefour (Figure4)

This text provides information on risk reduction of 16.1% with a p-value of 0.022. It also mentions the percentage of patients experiencing an event over a certain period of time (in months).*

FDA Label Image

Structuralformula (Structural Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.